EA201691018A1 - PHARMACEUTICAL COMPOSITION CONTAINING A MIXTURE OF PRODUCTS AND ENZYMES - Google Patents

PHARMACEUTICAL COMPOSITION CONTAINING A MIXTURE OF PRODUCTS AND ENZYMES

Info

Publication number
EA201691018A1
EA201691018A1 EA201691018A EA201691018A EA201691018A1 EA 201691018 A1 EA201691018 A1 EA 201691018A1 EA 201691018 A EA201691018 A EA 201691018A EA 201691018 A EA201691018 A EA 201691018A EA 201691018 A1 EA201691018 A1 EA 201691018A1
Authority
EA
Eurasian Patent Office
Prior art keywords
enzymes
mixture
pharmaceutical composition
composition containing
products
Prior art date
Application number
EA201691018A
Other languages
Russian (ru)
Other versions
EA033123B9 (en
EA033123B1 (en
Inventor
Франтишек Трнка
Павел Долезаль
Original Assignee
Франтишек Трнка
Павел Долезаль
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Франтишек Трнка, Павел Долезаль filed Critical Франтишек Трнка
Publication of EA201691018A1 publication Critical patent/EA201691018A1/en
Publication of EA033123B1 publication Critical patent/EA033123B1/en
Publication of EA033123B9 publication Critical patent/EA033123B9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • C12N9/2411—Amylases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6427—Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01003—Triacylglycerol lipase (3.1.1.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01001—Alpha-amylase (3.2.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21001—Chymotrypsin (3.4.21.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21004—Trypsin (3.4.21.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Фармацевтическая композиция, содержащая смесь проферментов и ферментов, содержащая проферменты: трипсиноген и химотрипсиноген и ферменты: α-амилазу и липазу в качестве активных веществ, и один или более фармацевтически приемлемых эксципиентов для одновременного, раздельного и последовательного введения композиции парентеральным или трансмукозальным путем, где композиция обладает антипролиферативными и антиметастатическими действиями в отношении раковых опухолей и предназначена для терапевтического, профилактического и антиметастатического применения у млекопитающих.A pharmaceutical composition containing a mixture of pro-enzymes and enzymes, containing pro-enzymes: trypsinogen and chymotrypsinogen and enzymes: α-amylase and lipase as active substances, and one or more pharmaceutically acceptable excipients for simultaneous, separate and sequential administration of the composition by parenteral or transmucosal route, where the composition possesses antiproliferative and antimetastatic actions against cancer tumors and is intended for therapeutic, prophylactic and antimette taticheskogo use in mammals.

EA201691018A 2013-11-18 2014-11-12 Anti-proliferative and anti-metastatic pharmaceutical composition and method of treating cancer EA033123B9 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZ2013-891A CZ307195B6 (en) 2013-11-18 2013-11-18 A pharmaceutical composition comprising a mixture of proenzymes and enzymes
PCT/CZ2014/000133 WO2015070828A1 (en) 2013-11-18 2014-11-12 Pharmaceutical composition containing a mixture of proenzymes and enzymes

Publications (3)

Publication Number Publication Date
EA201691018A1 true EA201691018A1 (en) 2016-11-30
EA033123B1 EA033123B1 (en) 2019-08-30
EA033123B9 EA033123B9 (en) 2019-10-31

Family

ID=67353809

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691018A EA033123B9 (en) 2013-11-18 2014-11-12 Anti-proliferative and anti-metastatic pharmaceutical composition and method of treating cancer

Country Status (16)

Country Link
US (2) US20160339085A1 (en)
EP (1) EP3071218B1 (en)
JP (1) JP6568095B2 (en)
CY (1) CY1121276T1 (en)
CZ (1) CZ307195B6 (en)
DK (1) DK3071218T3 (en)
EA (1) EA033123B9 (en)
ES (1) ES2707376T3 (en)
HR (1) HRP20182155T1 (en)
HU (1) HUE042667T2 (en)
LT (1) LT3071218T (en)
PL (1) PL3071218T3 (en)
PT (1) PT3071218T (en)
RS (1) RS58296B1 (en)
SI (1) SI3071218T1 (en)
WO (1) WO2015070828A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20121709A1 (en) * 2009-10-22 2012-12-17 Propanc Pty Ltd A PHARMACEUTICAL COMPOSITION TO TREAT CANCER INCLUDING TRYPSINOGEN AND / OR CHEMOTRIPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VAINILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCING AGENT
CZ307195B6 (en) 2013-11-18 2018-03-14 František Trnka A pharmaceutical composition comprising a mixture of proenzymes and enzymes
SG11201803531XA (en) * 2015-11-12 2018-05-30 Propanc Pty Ltd Proenzyme composition
CN105385669A (en) * 2015-11-24 2016-03-09 青岛康原药业有限公司 Method for extracting prekallikrein by secondary affinity chromatography and pharmaceutical composition for improving stability of prekallikrein
DK3407909T3 (en) * 2016-01-29 2023-11-13 Propanc Pty Ltd CANCER TREATMENT
WO2017177270A1 (en) * 2016-04-12 2017-10-19 Propanc Pty Ltd Composition of proenzymes for cancer treatment
DK3335696T3 (en) * 2016-12-15 2020-03-16 Upm Kymmene Corp Process for drying cell-free tissue extract in a hydrogel comprising nanofibrillar cellulose and a dried hydrogel comprising nanofibrillar cellulose and cell-free tissue extract
WO2021009768A1 (en) * 2019-07-12 2021-01-21 Lovely Professional University An oral pharmaceutical composition for alpha- amylase inhibition

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4514388A (en) * 1983-03-22 1985-04-30 Psaledakis Nicholas G Proteolytic enzymes in the zymogen form to treat sarcoma cells
US4844897A (en) 1985-09-13 1989-07-04 Hiroshi Maeda Anti-tumor protease preparations
CZ283972B6 (en) 1995-05-17 1998-07-15 František Mudr. Trnka Pharmaceutical preparation exhibiting modulation effect on malignant tumors and the use thereof
US6087558A (en) 1998-07-22 2000-07-11 Prodigene, Inc. Commercial production of proteases in plants
US6019468A (en) 1998-10-02 2000-02-01 Altemare, Jr.; Kenneth D. Spectacle kit
US6428785B1 (en) * 1999-10-28 2002-08-06 Immunolytics Inc. Method and composition for treating prostate cancer
AU2008218595B2 (en) * 2007-02-20 2012-05-24 Allergan Therapeutics LLC Stable digestive enzyme compositions
PE20121709A1 (en) 2009-10-22 2012-12-17 Propanc Pty Ltd A PHARMACEUTICAL COMPOSITION TO TREAT CANCER INCLUDING TRYPSINOGEN AND / OR CHEMOTRIPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VAINILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCING AGENT
CZ201124A3 (en) 2011-01-17 2012-06-13 Elmarco S.R.O. Carrier for oromucosal, especially sublingual application of physiologically active compounds
CN102949712A (en) * 2011-08-21 2013-03-06 李红彬 Chinese and western composite medicine for treating neoplastic diseases
US10087401B2 (en) 2012-03-16 2018-10-02 Monosol, Llc Water soluble compositions incorporating enzymes, and method of making same
CZ307195B6 (en) 2013-11-18 2018-03-14 František Trnka A pharmaceutical composition comprising a mixture of proenzymes and enzymes

Also Published As

Publication number Publication date
CZ2013891A3 (en) 2015-05-27
HRP20182155T1 (en) 2019-02-08
LT3071218T (en) 2018-12-27
ES2707376T3 (en) 2019-04-03
CY1121276T1 (en) 2020-05-29
US20190247471A1 (en) 2019-08-15
US20160339085A1 (en) 2016-11-24
WO2015070828A1 (en) 2015-05-21
JP2016538339A (en) 2016-12-08
EA033123B9 (en) 2019-10-31
EA033123B1 (en) 2019-08-30
JP6568095B2 (en) 2019-08-28
PL3071218T3 (en) 2019-05-31
SI3071218T1 (en) 2019-01-31
PT3071218T (en) 2019-01-30
EP3071218B1 (en) 2018-10-31
CZ307195B6 (en) 2018-03-14
DK3071218T3 (en) 2019-02-18
RS58296B1 (en) 2019-03-29
US11185587B2 (en) 2021-11-30
HUE042667T2 (en) 2019-07-29
EP3071218A1 (en) 2016-09-28

Similar Documents

Publication Publication Date Title
EA201691018A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING A MIXTURE OF PRODUCTS AND ENZYMES
PH12018502438A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
EA201990424A1 (en) SPIRALACTAM MODULERS OF NMDA RECEPTOR AND THEIR APPLICATION
EA201500857A1 (en) COMBINED VACCINES WITH SYNTHETIC NANO CARRIERS
WO2015123423A3 (en) Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy
EA201690618A1 (en) BLUTON TYROSINKINASE INHIBITORS
WO2015054619A8 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
WO2015019198A3 (en) High potency pancreatin pharmaceutical compositions
MX2021000898A (en) METHODS FOR TREATING PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (heFH).
EA201990428A1 (en) SPIRALACTAM MODULERS OF NMDA RECEPTOR AND THEIR APPLICATION
MX2015009773A (en) Spiro-lactam nmda receptor modulators and uses thereof.
BR112016022062A8 (en) combination, pharmaceutical composition, use of a combination or a pharmaceutical composition, and pharmaceutical product
EA201990425A1 (en) SPIRO-LACTAM AND BIS-SPIRO-LACTAM MODULATORS OF THE NMDA RECEPTOR AND THEIR APPLICATION
AR093181A1 (en) FORMULATION WITH CONTENT OF DIGESTIVE ENZYMES UNDER STABLE
MX2015009778A (en) Spiro-lactam nmda receptor modulators and uses thereof.
MX2016000480A (en) High potency pancreatin pharmaceutical compositions.
EA201792591A1 (en) PHARMACEUTICAL PREPARATIONS
IN2013MU00711A (en)
EA201591752A1 (en) DIPEPTIDE AND TRIPEPTID EPOXYETONIC PROTEASE INHIBITORS
MX2022002946A (en) Cdk inhibitors and their use as pharmaceuticals.
EA201501164A1 (en) SOLID PHARMACEUTICAL MEDICINE FORM
EA202090542A1 (en) HIGHLY CONCENTRATED MEDICINAL FORMS OF Pridopidine
MX2021004883A (en) Methods and compositions for treating sleep apnea.
MX2019005309A (en) Anti-bag3 antibodies in combination with inhibitors of immune check-point for therapeutic use.
EA201590796A1 (en) FIBRINOLYTIC COMPOSITIONS, INCLUDING BROMELEIN AND NATTOKINAZ, FOR THE PREVENTION AND TREATMENT OF PHLEBOTHROMBOTIC CONDITIONS

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent